We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Compassionate Use Study of Methylnaltrexone

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 8, 2011
Last Update Posted: July 19, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Valeant Pharmaceuticals International, Inc.
This is an open label compassionate use study of subcutaneously administered MNTX in subjects with advance medical illness and opioid-induced constipation. Eligible subjects were to initially receive a single dose of MNTX delivered SC. Subsequent dosing could have been adjusted upward to achieve a desired clinical response or lowered to alleviate drug related adverse events (AEs).

Condition Intervention
Opioid-induced Constipation Drug: Methylnaltrexone

Valeant Pharmaceuticals International, Inc. has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Compassionate Use Study of Methylnaltrexone in Patients With Opioid-Induced Side Effects

Resource links provided by NLM:

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • Number of patients with side effects of opioid-induced constipation. [ Time Frame: 6 months ]
    To provide subcutaneously administered MNTX to advanced medical illness patients on a compassionate basis in order to alleviate the side effects of opioid-induced constipation.

Enrollment: 26
Study Start Date: January 2003
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Drug: Methylnaltrexone


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Advanced medical illness (i.e. terminal illness, such as incurable cancer or end stage AIDS) with a life expectancy of one to six months
  2. On an opioid regimen for the control of pain/discomfort for at least seven days
  3. Has opioid-induced constipation
  4. On a laxative regimen (e.g. stool softener and SENNA or equivalent) for at least 3 days prior to treatment.

Exclusion Criteria:

  1. Patients with known hypersensitivity to methylnaltrexone, naltrexone or naloxone
  2. Patients who are constipated with a disease process suggestive of gastrointestinal obstruction, impaction or diagnosed with a current abdominal pathologic process which may represent a non-opioid cause of bowel dysfunction
  3. Patients who are constipated and have active, clinically significant diverticulitis
  4. Patients being treated with opioids for diarrhea, dyspnea, cough, pulmonary edema, or congestive heart failure
  5. Individuals with a known drug addiction.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01368562

United States, New York
Progenics Pharmaceuticals, Inc.
Tarrytown, New York, United States, 10591
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Study Director: Tage Ramakrishna, MD Progenics Pharmaceuticals, Inc.
  More Information

Responsible Party: Tage Ramakrishna, MD, Progenics Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01368562     History of Changes
Other Study ID Numbers: MNTX 901
First Submitted: May 27, 2011
First Posted: June 8, 2011
Last Update Posted: July 19, 2011
Last Verified: July 2011

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents